Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Market Cap 16TCr 2,71800Cr 14TCr 13TCr 12TCr 22TCr 14,93500Cr 22TCr 1,48100Cr 58TCr 7,31400Cr 59TCr 58TCr 25,34600Cr P/E Ratio 2026 *
-45.6x
P/E Ratio 2027 * 16.5x
Enterprise Value 17TCr 2,88200Cr 14TCr 13TCr 12TCr 23TCr 15,83900Cr 24TCr 1,57100Cr 61TCr 7,75700Cr 63TCr 62TCr 26,88100Cr EV / Sales 2026 *
5.5x
EV / Sales 2027 * 4.86x
Free-Float
99.87%
Yield 2026 *
2.55%
Yield 2027 * 2.61%
1 day-6.44%
1 week-6.44%
Current month-9.33%
1 month-6.88%
3 months-18.46%
6 months-1.27%
Current year-4.73%
1 month 2,117.15
Extreme 2117.15
2,335
Current year 2,117.15
Extreme 2117.15
2,618.71
1 year 2,025.32
Extreme 2025.32
2,618.71
3 years 1,046.71
Extreme 1046.71
2,618.71
5 years 1,046.71
Extreme 1046.71
2,618.71
10 years 1,046.71
Extreme 1046.71
2,618.71
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-6.44%-6.44% - - 16TCr
-0.61%-1.94%+39.00%+150.72% 1,00100Cr
-0.20%-0.77%+51.51%+43.20% 57TCr
+0.40%-1.31%+16.56%+60.47% 39TCr
-0.20%+2.29%+24.04%+16.53% 33TCr
+0.08%+0.57%+25.27%+31.78% 28TCr
+0.64%-0.80%+25.27%+14.68% 28TCr
+2.08%+1.06%-41.37%-47.16% 19TCr
-0.77%+0.95%+17.69%+51.46% 19TCr
+0.15%+1.32%+6.72%-35.00% 15TCr
Average -0.49%+0.60%+18.30%+31.85% 37.41TCr
Weighted average by Cap. -0.33%-0.25%+27.57%+63.16%

Financials

2026 *2027 *
Net sales 3.05TCr 52TCr 2.63TCr 2.42TCr 2.27TCr 4.26TCr 2,88200Cr 4.31TCr 29TCr 11TCr 1,41100Cr 11TCr 11TCr 4,89000Cr 3.25TCr 56TCr 2.8TCr 2.58TCr 2.42TCr 4.54TCr 3,06800Cr 4.59TCr 30TCr 12TCr 1,50200Cr 12TCr 12TCr 5,20700Cr
Net income -337.28Cr -5.8TCr -290.66Cr -267.66Cr -251.3Cr -471.83Cr -32TCr -476.81Cr -3.16TCr -1.23TCr -16TCr -1.27TCr -1.24TCr -54TCr 960.31Cr 17TCr 827.6Cr 762.08Cr 715.53Cr 1.34TCr 91TCr 1.36TCr 9.01TCr 3.51TCr 44TCr 3.6TCr 3.53TCr 1,54100Cr
Net Debt 956.82Cr 16TCr 824.59Cr 759.32Cr 712.93Cr 1.34TCr 90TCr 1.35TCr 8.97TCr 3.5TCr 44TCr 3.59TCr 3.51TCr 1,53500Cr -9.64Cr -165.9Cr -8.31Cr -7.65Cr -7.19Cr -13Cr -911.72Cr -14Cr -90Cr -35Cr -446.47Cr -36Cr -35Cr -1.55TCr
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
127.23USD
Average target price
157.57USD
Spread / Average Target
+23.85%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!